Second call to the Extraordinary General Meeting on March 8, 2023 – 02/16/2023 at 6:38 p.m.

Second call to the Extraordinary General Meeting on March 8, 2023

Paris, February 16, 2023

– 6:00 p.m. CET – Pixium Vision SA (Euronext Growth Paris – FR0011950641 – Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independently, informs its shareholders that its Extraordinary General Meeting, called to rule on the second call on the same agenda as the Extraordinary General Meeting of February 15, 2023, will be held on Wednesday March 8, 2023 at 10:30 a.m., at the Company’s registered office. The Extraordinary General Meeting of the Company initially scheduled for February 15, 2023 might not validly deliberate because the required quorum was not met. The shareholders present, having given proxy or having voted by mail represented together 16,101,576 shares out of the 77,190,979 shares with voting rights, i.e. a quorum representing 20.86% of the share capital.

The notice of the second meeting will be published in the BALO (Bulletin des Annonces Légales Obligatoires) on February 24, 2023 and will contain the terms of participation and voting at said meeting.

In accordance with the provisions of Articles R. 225-77 and R. 225-79 of the French Commercial Code, the proxy or postal voting forms received by the Company for the general meeting initially scheduled for February 15, 2023 remain valid as long as the book entry of the securities is maintained.

The shareholders had been informed of the agenda and the text of the resolutions of the general meeting, initially scheduled for February 15, 2023, in the notice of meeting published in BALO n°12 of January 27, 2023, which remain unchanged.

About Pixium Vision

Pixium Vision

creates a world of bionic vision to allow those who have lost their sight to recover their visual perception and gain autonomy. Pixium Vision’s bionic vision systems are associated with surgery and a period of rehabilitation. The Prima System’s wireless photovoltaic subretinal micro-implant is in clinical testing in patients who initially lost sight due to retinal degeneration due to the dry form of age-related macular degeneration (dry AMD) . Pixium Vision works closely with university partners and some of the most prestigious vision research institutions in the world, such as: Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, the Institute of Ocular Microsurgery (IMO) in Barcelona, ​​the University Hospital in Bonn and the UPMC in Pittsburgh (Pennsylvania, USA). The Company is EN ISO 13485 certified and has received the “Innovative Company” qualification from Bpifrance.

For more information:

http://www.pixium-vision.com/fr

follow us on

@PixiumVision

;

www.facebook.com/pixiumvision

www.linkedin.com/company/pixium-vision

Contacts

Pixium Vision Offer Nonhoff Financial director [email protected] [phone]

Relations presse LifeSci Advisors Sophie Baumont [email protected] [phone]

Investor Relations LifeSci Advisors Guillaume van Renterghem [email protected] [phone]

Attachment

• Pixium Vision – AGE 15 02 2023 – CP Seconde convocation de l’AGE – FR